Mergers & Acquisitions
Filter News
Found 19,155 articles
-
Venture capitalist Chamath Palihapitiya is raising $800 million to finance four more special purpose acquisition companies that will be focused on taking biotech companies public.
-
venBio Global Strategic Fund IV will invest primarily in drug companies focused on developing therapies for unmet medical needs.
-
Vynca Acquires Virtual Palliative Care Provider ResolutionCare, Introduces Serious Illness Management Platform
6/3/2021
Vynca, a national leader in advance care planning, today announced that it has acquired California-based ResolutionCare, an innovator and provider of home-based palliative care and telemedicine.
-
Novo Integrated Sciences Enters into Share Exchange Agreement to Acquire Acenzia Inc.
6/3/2021
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company”) is pleased to announce the signing of a Share Exchange Agreement, dated May 28, 2021 (the “SEA”), pursuant to which Novo Healthnet Limited, a wholly owned subsidiary of the Company (“NHL”) will acquire Acenzia Inc.
-
Bayer Acquires Noria and PSMA Therapeutics to Expand Pipeline in Prostate Cancer
6/3/2021
Bayer today announced that it has entered into an agreement to acquire Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc.
-
Auris Medical Announces Acquisition of RNA Therapeutics Company and Plans for Strategic Repositioning
6/3/2021
Entering field of RNA therapeutics through acquisition of Trasir Therapeutics, Inc. Trasir’s innovative peptide-based OligoPhore TM platform designed to enable extrahepatic delivery of oligonucleotides
-
ALK Acquires OTIPRIO® (ciprofloxacin otic suspension), Broadening Treatment Solutions for Healthcare Providers and Patients
6/3/2021
ALK (ALKB:DC / OMX:ALK B / AKABY / AKBLF), a global, research-driven pharmaceutical company that focuses on the diagnosis and treatment of allergies, announced today that it has acquired OTIPRIO® (ciprofloxacin otic suspension) from Otonomy, Inc
-
MorphoSys is acquiring Constellation Pharmaceuticals for about $1.7 billion. It is a stock deal at $34 per share in cash. Morphosys also announced a partnership with Royalty Pharma, with Royalty paying MorphoSys $1.425 billion up front.
-
AliveCor Acquires CardioLabs and Sets the Stage for the Launch of Advanced Ambulatory Monitoring Services
6/2/2021
AliveCor , the global leader in FDA-cleared personal electrocardiogram (ECG) technology and services, today announced that it has acquired the independent diagnostic testing facility (IDTF) CardioLabs, a leading monitoring and cardiac diagnostic service provider.
-
Spectrum Announces Acquisition of Unique Surface Technology for Spinal Trauma
6/2/2021
Spectrum Spine, spinal device supplier and leader in the development of spinal surgical device inventions, announced that it has acquired a highly unique and proprietary surface technology for spinal trauma and has begun operations with the device.
-
Arcline Investment Management Acquires Resolution Medical
6/2/2021
Arcline Investment Management ("Arcline"), a growth-oriented private equity firm, today announced that it has acquired a controlling stake in Resolution Medical, LLC
-
Applied DNA Adds First Summer Camp for safeCircle Pooled COVID-19 Surveillance Testing
6/2/2021
Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that its wholly-owned subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has secured a safeCircle™ pooled COVID-19 surveillance testing contract with Camp Chateaugay , an overnight summer camp program for teens and kids based in New York’s Adirondack Mountain region
-
Oncodisc Inc. Acquired by PAVmed Digital Health Company Veris Health Inc.
6/2/2021
Oncodisc Inc. ("Oncodisc") today announced that it was acquired by Veris Health Inc ("Veris"), a majority owned digital health subsidiary of PAVmed Inc. ("PAVmed").
-
Sorrento Completes Acquisition of ACEA Therapeutics, Creating a Major Oncology Franchise
6/2/2021
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has completed the acquisition of ACEA Therapeutics Inc. (“ACEA”).
-
MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma
6/2/2021
MorphoSys AG (FSE:MOR) announces today that it has entered into a definitive agreement with Constellation Pharmaceuticals, Inc. (NASDAQ: CNST) whereby MorphoSys will acquire Constellation for $34.00 per share in cash, which represents a total equity value of $1.7 billion.
-
STERIS Completes the Acquisition of Cantel Medical
6/2/2021
STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that it has completed the previously announced acquisition of Cantel Medical, a global provider of infection prevention products and services to endoscopy, dental, dialysis and life sciences Customers.
-
MorphoSys to Acquire Constellation Pharmaceuticals
6/2/2021
Accelerates Growth Strategy by Adding Two Mid- to Late-Stage Product Candidates: Pelabresib (CPI-0610) and CPI-0209 Bolsters Position in Hematology-Oncology and Expands into Solid Tumors Best-in-Class Combined Discovery and Development Capabilities Accelerates Ability to Provide New Cancer Treatments to Patients MorphoSys Enters into Strategic Funding Partnership with Royalty Pharma
-
AmerisourceBergen Completes Acquisition of Alliance Healthcare Businesses
6/2/2021
AmerisourceBergen Corporation announced the completion of its acquisition of the majority of Walgreens Boots Alliance’s Alliance Healthcare businesses for $6.275 billion in cash, subject to a customary working capital and net debt adjustment, and 2 million shares of AmerisourceBergen common stock.
-
IDEXX Acquires ezyVet
6/2/2021
Global leader in veterinary diagnostics and software enhances its practice management portfolio with acquisition of leading cloud-based solution
-
Aceto Propels Growth Strategy with Cascade Chemistry Acquisition
6/2/2021
Aceto, a leading global provider of specialty materials for life sciences and advanced technology end markets, announced the acquisition of Eugene, Oregon-based Cascade Chemistry, manufacturer of active pharmaceutical ingredients, regulatory starting materials and advanced intermediates.